GlassScriptPhysician profile
Amanda Dawn Smith
NPI 1205503927
$2,446.64
in general payments reported to CMS, 2019-2025
14 companies · $519 in 2025
The $519 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $349 · 2023: $468 · 2024: $1,111 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.86 | 2023-2025 | |
| Lilly USA, LLC | $363.71 | 2022-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $266.28 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $227.51 | 2022-2024 | Repatha |
| Glaxosmithkline, LLC. | $214.77 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Corium, LLC | $204.25 | 2022-2025 | Azstarys |
| Novo Nordisk INC | $184.92 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $99.92 | 2024-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $95.17 | 2024-2025 | |
| Dexcom, INC. | $83.16 | 2022 | |
| Astellas Pharma US INC | $59.69 | 2024-2025 | Veozah |
| Pfizer INC. | $36.73 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.98 | 2024 | Caplyta |
| Ibsa Pharma INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.